Feladilimab
- Generic Name
- Feladilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- OUP4QB2A3R
- Background
Feladilimab is under investigation in clinical trial NCT04128696 (Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 105
- Registration Number
- NCT05553808
- Locations
- πΈπͺ
GSK Investigational Site, Uppsala, Sweden
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 117
- Registration Number
- NCT04428333
- Locations
- π¬π§
GSK Investigational Site, Sutton, United Kingdom
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 315
- Registration Number
- NCT04128696
- Locations
- π¬π§
GSK Investigational Site, Sutton, United Kingdom
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 464
- Registration Number
- NCT04126200
- Locations
- πΈπͺ
GSK Investigational Site, Stockholm, Sweden
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 176
- Registration Number
- NCT03739710
- Locations
- πΈπͺ
GSK Investigational Site, Uppsala, Sweden
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 26
- Registration Number
- NCT03693612
- Locations
- π¨π¦
GSK Investigational Site, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2024. All Rights Reserved by MedPath